Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.